Related Experiment Videos

2-acetaminofluorene blocks cell cycle progression after hepatectomy by p21 induction and lack of cyclin E expression

C Trautwein1, M Will, S Kubicka

  • 1Department of Gastroenterology & Hepatology, Medizinische Hochschule Hannover, Germany.

Oncogene
|December 22, 1999
PubMed

Insights

Hepatocellular carcinoma development in rats involves 2-Acetaminofluorene (AAF) blocking hepatocyte proliferation. This study reveals AAF inhibits cell cycle progression via p53/p21 and lack of Cyclin E, preventing DNA synthesis.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Carcinogenesis

Background:

  • The Solt-Faber model uses DENA and 2-Acetaminofluorene (AAF) with hepatectomy to induce hepatocellular carcinoma in rats.
  • AAF treatment inhibits hepatocyte proliferation, while oval cells are involved in liver mass restoration.

Purpose of the Study:

  • To investigate the molecular mechanisms by which AAF blocks hepatocyte cell cycle progression in vivo.
  • To understand the role of specific cell cycle regulators in AAF-induced liver cancer.

Main Methods:

  • Utilized the Solt-Faber rat model.
  • Analyzed cell proliferation using immunofluorescence for Cyclin E.
  • Assessed protein expression (p53, RB) and mRNA levels (p21) via molecular assays.

Main Results:

  • AAF treatment inhibited hepatocyte proliferation, evidenced by absent Cyclin E in hepatocytes but present in oval cells.
  • AAF induced strong nuclear p53 expression and increased p21 mRNA levels.
  • Decreased RB expression and phosphorylation were observed, impairing E2F complex formation and DNA synthesis.

Conclusions:

  • AAF-dependent cell cycle arrest in hepatocytes is mediated by two key mechanisms: p53 induction leading to elevated p21, and a lack of Cyclin E at the G1/S restriction point.
  • These molecular events contribute to the development of hepatocellular carcinoma in the Solt-Faber model.

Related Concept Videos